

Title Page

**The Molecular Mechanism Regulating Diurnal Rhythm of Flavin-containing
Monooxygenase 5 in Mouse Liver**

Min Chen, Baozhang Guan, Haiman Xu, Fangjun Yu, Tianpeng Zhang, Baojian Wu

Research Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy, Jinan University, Guangzhou, China (MC, HX, YF, TZ and BW); Department of Nephrology, the First Affiliated Hospital of Jinan University, Guangzhou, China (BG); International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, China (MC and BW).

Running Title Page

Running Title: Regulatory mechanism for diurnal Fmo5

Address correspondence to:

Baojian Wu, Ph.D.

College of Pharmacy, Jinan University, Guangzhou China

E-mail: bj.wu@hotmail.com

Tianpeng Zhang, Ph.D.

College of Pharmacy, Jinan University, Guangzhou China

E-mail: tp.zhang@outlook.com

Number of Text Page:	37
Number of Tables:	3
Number of Figures:	8
Number of References:	45
Number of Words in Abstract:	243
Number of Words in Introduction:	678
Number of Words in Discussion:	881

Non-standard abbreviations:

Bmal1, brain and muscle arnt-like protein-1; Clock, circadian locomotor output cycles kaput; Cry, cryptochrome; Dbp, D-box binding protein; E4bp4, E4 promoter-binding protein 4; Fmo5/FMO5, mouse/human flavin-containing monooxygenase 5; Per, period; siRNA, short interfering RNA; siNC, short interfering RNA for negative control; siBmal1, short interfering RNA for Bmal1; siE4bp4, short interfering RNA for E4bp4; siRev-erba, short interfering RNA for Rev-erba; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; IBMX, 3-isobutyl-1-methyl xanthine; PTX, pentoxifylline; CHIP, chromatin immunoprecipitation assay; qPCR, quantitative reverse transcription polymerase chain reaction; UPLC-QTOF/MS, ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry; ZT, zeitgeber time.

Abstract

Flavin-containing monooxygenase 5 (FMO5) is a phase I enzyme that plays an important role in xenobiotic metabolism. Here, we aimed to characterize diurnal rhythms of Fmo5 expression and activity in mouse liver, and to investigate the potential roles of circadian clock genes (*Bmal1*, *Rev-erba* and *E4bp4*) in generation of diurnal rhythms. Fmo5 mRNA and protein showed robust diurnal rhythms with peak values at zeitgeber time (ZT) 10/14 and trough values at ZT2/22 in mouse liver. Consistently, a diurnal rhythm was observed for *in vitro* microsomal Baeyer-Villiger oxidation of pentoxifylline (PTX), a specific reaction catalyzed by Fmo5. Pharmacokinetic studies revealed a more extensive Baeyer-Villiger oxidation of PTX at dosing time of ZT14 than at ZT2 consistent with the diurnal pattern of Fmo5 protein. Fmo5 expression was down-regulated and its rhythm was blunted in *Bmal1*^{-/-} and *Rev-erba*^{-/-} mice. Positive regulation of Fmo5 by Bmal1 and Rev-erba was confirmed in primary mouse hepatocytes and/or Hepa1-6 cells. Furthermore, Fmo5 expression was up-regulated and its rhythm was attenuated in *E4bp4*^{-/-} mice. Negative regulation of Fmo5 by E4bp4 was validated using primary mouse hepatocytes. Combined luciferase reporter and chromatin immunoprecipitation assays demonstrated that Bmal1 (a known Rev-erba activator) activated *Fmo5* transcription via direct binding to an E-box (-1822/-1816 bp) in the promoter, whereas E4bp4 (a known Rev-erba target gene) inhibited *Fmo5* transcription by binding to two D-boxes (-1726/-1718 and -804/-796 bp). In conclusion, circadian clock genes control diurnal expression of Fmo5 through transcriptional actions on E-box and D-box cis-elements.

Significance statement

Hepatic *Fmo5* displayed diurnal rhythmicities in expression and activity in mice. We uncovered the molecular mechanism by which the rhythmic *Fmo5* expression was generated. *Fmo5* promoter presents E-box and D-box binding elements for transcriptional actions from circadian clock proteins such as Bmal1, E4bp4 and Dbp. These findings have implications for understanding of clock-controlled drug metabolism and for facilitating the practice of chronotherapeutics.

Introduction

Flavin-containing monooxygenases (FMOs) are a family of phase I enzymes involved in metabolism of numerous drugs (e.g., benzydamine, methimazole and albendazole) and environmental toxicants (e.g., insecticides, fonfos and aldicarb) (Rendic et al., 2015; Krueger et al., 2005). There are five functional *FMO* genes in humans, namely, *FMO1*, *FMO2*, *FMO3*, *FMO4*, and *FMO5*. The former four genes are clustered in the region 1q24.3 of chromosome 1, whereas *FMO5* is located at 1q21.1. There are the same number of functional *Fmo* genes in mice. *Fmo1*, 2, 3, and 4 are clustered on chromosome 1 and *Fmo5* is located on chromosome 3 (Hernandez et al., 2004). Of *FMO* genes, *FMO5* is highly expressed in the liver in both humans and rodents (Janmohamed et al., 2004; Cashman et al., 2006). A growing body of literature has revealed a critical role for human *FMO5* in metabolism of drugs/metabolites including pentoxifylline (PTX), nabumetone, E7016, and S-methyl-esonarimod (an active metabolite of the anti-rheumatic esonarimod) (Fiorentini et al., 2017; Lai et al., 2011; Ohmi et al., 2003). In addition, *Fmo5* regulates metabolic aging via pleiotropic effects including effects on fatty acid oxidation and biosynthesis of triglyceride, lipid and cholesterol (Gonzalez Malagona et al., 2015).

PTX is a phosphodiesterase inhibitor used to treat peripheral vascular diseases, inflammatory, and immune diseases (Samlaska et al., 1994). PTX is mainly cleared from

the body via phase I metabolism (Nicklasson et al., 2002; Raoul et al., 2007; Malátková et al., 2014; Uney et al., 2019). Seven phase I metabolites (denoted by M1-M7) can be generated from PTX in humans (Nicklasson et al., 2002). Recently, Fiorentini et al (2017) identified a new metabolic pathway (i.e., Baeyer-Villiger oxidation) for PTX that is exclusively catalyzed by FMO5. This oxidation reaction may be used to probe the enzymatic activity of FMO5 (Fiorentini et al., 2017).

Many aspects of mammalian behaviors and physiology such as sleep-wake cycles, heartbeat, blood pressure, and body temperature are subject to circadian rhythms (Ralph et al., 1990; Gachon et al., 2011). Circadian rhythms are driven by central clock located in the suprachiasmatic nuclei (SCN) of the hypothalamus and peripheral clocks present in peripheral tissues (Ralph et al., 1990; Ohdo et al., 2001; Gachon et al., 2011). At the molecular level, clock system consists of a set of clock genes/proteins [including BMAL1 (brain and muscle Arnt-like protein-1), CLOCK (circadian locomotor output cycles kaput), CRY (cryptochrome) and PER (period)] that operate using a transcriptional-translational feedback mechanism (Reppert et al., 2002). BMAL1 and CLOCK proteins form a heterodimer to activate the transcription of *CRY* and *PER* and other clock-controlled genes (CCGs). When reaching a critical level, CRY and PER proteins inhibit BMAL1/CLOCK transactivation and down-regulate their own expressions and the expressions of other CCGs (Gekakis et al., 1998; Johnson et al., 1999). Thereby, the circadian clock generates oscillations in the expressions of CCGs.

Many drug-metabolizing enzymes (DMEs) including several CYPs display circadian rhythms in their expressions (Zhang et al., 2009). Circadian expressions of DMEs are associated with dosing time-dependent drug toxicity/tolerance and effects (Le'vi et al., 2010; Paschos et al., 2010). This knowledge may be exploited in optimization of dosing regimen to minimize drug toxicity and maximize efficacy. Circadian clock genes appear to control the rhythmic expressions of DMEs using direct or indirect transcriptional mechanisms. For instance, *Bmal1* regulates diurnal expression of *Sult1a1* through direct binding to an E-box in the promoter (Guo et al., 2018). *Rev-erba* regulates the circadian *Ugt2b* expression via binding to a RevRE element (Zhang et al., 2018). The PAR bZip (proline and acidic amino acid rich basic-leucine zipper) transcription factors (*Dbp*, *Hlf* and *Tef*) control rhythmic expression of *Cyp2b10* through transactivation of *Car* receptor (Paschos et al., 2010).

To date, the diurnal rhythmicities of FMOs (non-CYP phase I enzymes) remain unexplored. In this study, we aimed to characterize diurnal rhythms of *Fmo5* expression and activity in mouse liver, and to investigate the potential roles of circadian clock genes (*Bmal1*, *Rev-erba* and *E4bp4*) in generation of diurnal rhythms. We for the first time demonstrated that circadian clock genes control diurnal expression of *Fmo5* through transcriptional actions on E-box and D-box cis-elements.

Materials and Methods

Materials

Pentoxifylline (PTX) and 3-isobutyl-1-methyl xanthine (IBMX) were purchased from MCE (Monmouth Junction, NJ). Anti-Fmo5 (13699-1-AP) and anti-E4bp4 (11773-1-AP) antibodies were purchased from Proteintech (Chicago, IL). Nicotinamide adenine dinucleotide phosphate (NADPH), anti-Rev-erba (WH0009572M2) antibody and Dulbecco's modified Eagle's medium (DMEM, high glucose) were purchased from Sigma-Aldrich (St Louis, MO). Anti-Dbp (sc-32899) antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Gapdh (ab181602) and anti-Bmal1 (ab3350) antibodies were obtained from Abcam (Cambridge, MA). The transfection reagent jetPRIME™ was purchased from Polyplus Transfection (Illkirch, France). Fetal bovine serum (FBS) and trypsin were obtained from Hyclone (Logan, UT). siRNA targeting *Bmal1*, *Rev-erba*, and *E4bp4* (named siBmal1, siRev-erba, and siE4bp4, respectively, sequences provided in Table 1) were obtained from Transheep Bio-Tech (Shanghai, China). pRL-TK vector was purchased from Promega (Madison, WI).

Biosynthesis of PTX-M

PTX-M was generated using human FMO5 supersomes (BD-Biosciences-Gentest, Woburn, MA) according to the microsomal metabolism assay protocol with a scaling factor of 10. Crude PTX-M (~10 mg) was isolated and purified as described (Fiorentini et

al., 2017). In brief, the microsomal reactions were performed in centrifugal tube (total incubation volume: 2 ml) for 2 h at 37°C. The resulting mixture was extracted with ethyl acetate and the combined organic phases from 30 replicates were using Eppendorf Concentrator Plus (Hamburg, Germany). After reconstitution in dichloromethane, the crude extract was purified via chromatography on silica gel by using ethyl acetate/triethylamine (99:1, v/v), yielding about 2.0 mg of PTX-M. The product was verified by UPLC-QTOF/MS analysis, showing an extract mass of m/z 295.14, and MS² fragments of 252.13 and 181.08 (see Supplementary Figure S1 for the fragmentation pathway).

Animal studies

Male wild-type (WT) C57BL/6 mice were purchased from HFK Biotechnology (Beijing, China). *Bmal1*^{-/-} (a C57BL/6 background) mice were obtained from Bioray Laboratories (Shanghai, China) (Guo et al., 2018). *Rev-erba*^{-/-} (a C57BL/6 background) mice were obtained from Cyagen Biosciences (Guangzhou, China) (Wang et al., 2018). *E4bp4*^{-/-} (a C57BL/6 background) mice were obtained from Dr. Masato Kubo (the Center for Integrative Medical Sciences, RIKEN, Japan) (Zhao et al., 2018). The control littermates of *Bmal1*^{-/-}, *Rev-erba*^{-/-}, and *E4bp4*^{-/-} mice are named *Bmal1*^{+/+}, *Rev-erba*^{+/+}, and *E4bp4*^{+/+}, respectively. All mice were housed and maintained under a 12 h light/12 h dark cycle [lights on at 7:00 AM (=ZT0) and lights off at 7:00 PM (=ZT12)], with food and water ad libitum at Institute of Laboratory Animal Science (Jinan University, Guangzhou, China).

Animal experiments were approved by Institutional Animal Care and Use Committee of Jinan University (Guangzhou, China). For diurnal expression profiling, liver tissues were collected from mice (male, 8-10 weeks old, $n = 5$ per group) every 4 h over a 24 h LD cycle at ZT2, ZT6, ZT10, ZT14, ZT18, and ZT22. The samples were subjected to qPCR and Western blotting assays.

For pharmacokinetic studies, PTX (50 mg/kg) was administered to WT mice (male, 8-10 weeks) by intraperitoneal injection (i.p.) at ZT2 or ZT14. At predetermined time points (5, 10, 15, 20, 30, 60, 120, and 240 min), mice ($n = 5$ per time point) were rendered unconscious with isoflurane. Blood was sampled via a cardiac puncture and centrifuged at 8,000 g for 8 min to collect the plasma. Livers were immediately collected, snap frozen in liquid nitrogen and stored at -80°C . Frozen liver (100 mg) was added two volumes of ice cold saline, minced and homogenized with IKA T25-Digital Ultra-Turrax (Staufen, Germany). Plasma and liver homogenates were mixed with methanol (1:10, v/v) (containing IBMX, an internal standard), vortexed for 3 min, and centrifuged at 13,000 g for 15 min. The supernatant was collected and dried using Eppendorf Concentrator Plus (Hamburg, Germany). The residue was reconstituted in 200 μl of water/methanol (50:50, v/v), and centrifuged at 13,000 g for 15 min. The supernatant was injected into a UPLC-QTOF/MS system for drug and metabolite quantification (Waters, Milford, MA).

qPCR assay

Total RNA was extracted from mouse liver or cell samples with TRIzol reagent (Invitrogen) following the manufacturer's instructions. cDNAs were synthesized from total RNA using a PrimeScript RT Master Mix (Takara Bio., Shiga, Japan). qPCR reactions were performed with GoTap qPCR Master Mix (Promegaa, Wadison, WI) using a Biometra Toptical Thermocycler (Analytik Jena, Goettingen, Germany) as described in our previous publication (Guo et al., 2018). The relative expression was determined using the $2^{-\Delta\Delta CT}$ method. Peptidylprolyl isomerase B (*Ppib*) was used as an internal control. All primer sequences are provided in Table 1.

Western blotting

Mouse tissues or cell samples were lysed in RIPA buffer (with 1 mM PMSF). Protein concentrations were determined using a BCA assay kit (Beyotime, Shanghai, China). Protein samples (40 μ g) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane. The membrane was incubated with the primary antibody overnight at 4°C after blocked with 5% nonfat milk in TBST for 1 h, and then incubated with the secondary antibody for 1 h at room temperature. Protein bands were visualized with enhanced chemiluminescence using an Omega LumG Imaging System (Aplegen, Pleasanton, CA) and analyzed by the Quantity One software. Protein levels were normalized to Gapdh and expressed as

relative values.

Quantification of PTX and its metabolite

PTX and PTX-M (an oxidized metabolite of PTX) were quantified using an UPLC-QTOF/MS system (Waters, Milford, MA) and a BEH C18 column (2.1 × 50 mm, 2.6 μm; Waters, Milford, MA). The mobile phases were 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). The flow rate was set at 0.3 ml/min. The gradient elution program was 10% B at 0 to 2 min, 10 to 90% B at 2 to 3.5 min, 90% B at 3.5 to 4.5 min, and 90 to 10% B at 4.5 to 5 min. Mass spectrometer was operated in positive ion mode. The capillary, sampling cone, and extraction cone voltages were set at 3000, 30, and 4 V, respectively. The source and desolvation temperatures were 100°C and 350°C, respectively. Peak areas of PTX, PTX-M and IBMX (internal standard) were recorded with extract masses of m/z 279.15 ± 0.05 Da, 295.14 ± 0.05 Da and 223.01 ± 0.05 Da, respectively. Representative extracted ion chromatograms are provided in Supplementary Figure S1. The calibration curves for PTX and PTX-M were linear ($r^2 > 0.99$) over the entire concentration range (i.e., 9.766-1250 ng/ml for PTX and 2-600 ng/ml for PTX-M).

Plasmid construction

Mouse *Bmal1* (GenBank accession number: NM_007489.4), *Rev-erba* (GenBank accession number: NM_145434.4), *E4bp4* (GenBank accession number: NM_017373.3),

and *Dbp* genes (GenBank accession number: NM_016974.3) were synthesized and cloned into the expression vector pcDNA3.1 (Biowit Technologies, Shenzhen, China). *Fmo5* luciferase (*Fmo5*-Luc) reporter constructs with different promoter fragments (i.e., -2000/+100, -1190/+100, -910/+100, and -600/+100 bp) and mutated versions were synthesized and cloned into the pGL4.17 vector (Kaile Bio-Tech, Guangzhou, China). The plasmids were transformed into *Escherichia coli* JM109 and extracted using an EasyPure HiPure Plasmid MiniPrep kit (TransGen Biotech, Beijing, China).

Isolation and culture of primary mouse hepatocytes

Primary hepatocytes were isolated from WT mice as previously described (Zhang et al., 2012; Zhang et al., 2018). In brief, mice were rendered unconscious with isoflurane. The liver was perfused with HBSS buffer through portal vein, and digested with collagenase IV. After washing three times with HBSS buffer, hepatocytes were collected and cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. 3 h later, the medium was changed to serum-free DMEM. On the next day, the cells were used for transfection.

Cell transfection

Mouse hepatoma Hepa1-6 cells were purchased from the American Type Culture Collection (Rockville, MA). Cells were seeded into a 6-well plate and cultured in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO₂ atmosphere. Cells were

transfected with Bmal1, Rev-erb α , E4bp4 plasmid (2 μ g per well), siBmal1, siRev-erb α , siE4bp4 (50 μ M) or control using the jetPRIME™ transfection reagent (Polyplus Transfection, Illkirch, France). After 48 h transfection, cells were collected for qPCR and Western blotting analyses.

Serum shock experiments

Serum shock experiments were performed to induce circadian gene expression in Hepa1-6 cells as previously described (Matsunaga et al., 2012). In brief, Hepa1-6 cells were cultured in DMEM supplemented with 10% FBS. Once reaching a confluence of 80%, the culture medium was changed to serum-free DMEM. 12 h later, 50% FBS was added to the medium. After 2 h serum shock, the medium was changed back to serum-free DMEM, and the cells were collected at specific time points (0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48 h) for qPCR assays.

Microsomal metabolism assay

Livers were collected from the WT mice every 4 h over a 24 h LD cycle at ZT2, ZT6, ZT10, ZT14, ZT18, and ZT22. Mouse liver microsomes were prepared by sequential ultracentrifugation, first at 9,000 g for 10 min and then at 100,000 g for 1 h (Zhang et al., 2018). The protocol for microsomal incubation assay (*in vitro* Baeyer-Villiger oxidation reaction) was adapted from Lai et al (2011). In brief, the incubation mixture (a total volume of 200 μ l) contained 50 mM potassium phosphate buffer (pH 7.4), 2 mg/ml liver

microsomes, 2.5 mM NADPH, and 500 μ M PTX. After 2 h incubation (under a linear condition) at 37°C, the reaction was terminated by adding 200 μ l ice-cold water/acetonitrile (50:50, v/v) (containing IBMX, an internal standard). The resulting mixture was centrifuged at 2,000 g for 10 min, and the supernatant was subjected to UPLC-QTOF/MS analysis as described in the section of *Quantification of PTX and its metabolite*. The calibration curve for PTX-M was linear ($r^2 > 0.99$) over the entire concentration range (i.e., 31.3-2000 nM for PTX-M).

Luciferase reporter assay

HEK293T cells were purchased from the American Type Culture Collection (Rockville, MA). HEK293T cells were seeded into 48-well plates. After 24 h, cells were transfected with 200 ng of *Fmo5* luciferase (firefly) reporter plasmid, 10 ng of pRL-TK vector (an internal control with renilla luciferase gene), and overexpression plasmid (*Bmal1*, *E4bp4*, or *Dbp* plasmid). Different amounts (100, 200 and 300 ng) of overexpression plasmids were tested. Control experiments were performed with the blank plasmid pcDNA3.1. After 24 h transfection, cells were collected and the luciferase activities were measured using the Dual-Luciferase Reporter Assay system and GloMax 20/20 Luminometer (Promega).

ChIP assay

ChIP assays were performed using an Enzymatic Chromatin IP kit (Cell Signaling

Technology, Beverly, MA) as previously described (Chen et al., 2019). In brief, mouse liver was fixed in 37% formaldehyde for 15 min at room temperature and the reaction was stopped by glycine. The nuclei were obtained from cross-linked samples with lysis buffers and digested with micrococcal nuclease. The lysate was sonicated 8 times (9 s each time) with an interval of 30 s to shear DNAs. The sheared chromatin (an average fragment size of 200 bp) was immunoprecipitated overnight with anti-Bmal1 (Abcam, Cambridge, MA), anti-E4bp4 (Proteintech, Chicago, IL), anti-Dbp (Santa Cruz, CA), or normal rabbit IgG (control) at 4°C. The chromatin was decross-linked at 65°C for 2 h and purified with spin columns. The purified DNAs were analyzed by qPCR with specific primers (Table 1).

Statistical analysis

Data are presented as means \pm SD (standard deviation). Student's t-test was used to analyze the statistical differences between two groups. One-way or two-way ANOVA followed by Bonferroni post hoc test was used for multiple group comparisons. The level of significance was set at $p < 0.05$ (*).

Results

Diurnal rhythms of Fmo5 expression and activity in mouse liver

Fmo5 mRNA in mouse liver oscillated in a circadian time-dependent manner that peaked at around ZT10 (Figure 1A). Likewise, Fmo5 protein showed a significant diurnal rhythm (Figure 1B). Human FMO5 specifically catalyzes the formation of an oxidized metabolite (PTX-M) from PTX, also known as a Baeyer-Villiger oxidation reaction (Figure 1C) (Fiorentini et al., 2017). We confirmed an exclusive activity of mouse Fmo5 in generating PTX-M from PTX (Supplementary Figure S2). *In vitro* microsomal metabolism assays with PTX revealed a robust diurnal oscillation in Fmo5 activity consistent with the enzyme's rhythmic expression (Figure 1D). We also observed rhythmic expression of Fmo5 in serum-shocked Hepa1-6 cells (Figure 1E). These data supported *Fmo5* as a circadian gene.

Circadian time-dependent *in vivo* activity of Fmo5

We next attempted to assess circadian time-dependent activity of Fmo5 *in vivo* by performing pharmacokinetic studies with PTX [dosed at a different circadian point (i.e., ZT2 or ZT14)]. Dosing time did not cause a significant difference in PTX pharmacokinetics, although ZT14 generated slight decreases in plasma and liver PTX concentrations compared to ZT2 (Figure 2A/B & Table 2). In contrast, a significant dosing time effect was observed for PTX metabolism (i.e., formation of PTX-M). Both plasma

and liver levels of PTX-M were higher at dosing time of ZT14 than at ZT2 (Figure 2C/D). Accordingly, higher AUC (the area under the curve) values of PTX-M were observed for ZT14 (Table 3). The data indicated circadian time-dependent PTX-M formation in mice that was attributed to a diurnal rhythmicity in Fmo5 activity.

Disrupted Fmo5 rhythms in *Bmal1*^{-/-}, *Rev-erba*^{-/-}, and *E4bp4*^{-/-} mice

Circadian gene expression is generally produced by a transcriptional mechanism in which core clock genes act on three cis-elements (E-box, D-box and RevRE or RORE) in target gene promoter (Minami et al., 2013). We thus first investigated the roles of the three cis-elements in generation of rhythmic Fmo5 expression using *Bmal1*^{-/-}, *E4bp4*^{-/-}, and *Rev-erba*^{-/-} mice. Bmal1, E4bp4 and Rev-erba are respective representative cis-acting proteins for E-box, D-box and RevRE. The rhythms of Fmo5 mRNA and protein were blunted in *Bmal1*^{-/-}, *Rev-erba*^{-/-}, and *E4bp4*^{-/-} mice compared to their littermates (Figure 3A/B). Fmo5 levels were generally down-regulated in *Bmal1*^{-/-} and *Rev-erba*^{-/-}, but up-regulated in *E4bp4*^{-/-} mice (Figure 3A/B). These data indicated that circadian clock genes *Bmal1*, *Rev-erba*, and *E4bp4* can modulate rhythmic Fmo5 expression probably through their own cis-elements.

Bmal1 positively regulates Fmo5 expression in cells

The regulatory effects of Bmal1 on Fmo5 expression were evaluated using primary mouse hepatocytes and Hepa1-6 cells. Overexpression of Bmal1 led to significant

increases in Fmo5 mRNA and protein in primary mouse hepatocytes (Figure 4A/B). By contrast, knockdown of Bmal1 by siRNA caused decreases in Fmo5 mRNA and protein (Figure 4A/B). Likewise, Bmal1 overexpression resulted in increased, whereas Bmal1 knockdown led to reduced Fmo5 expression in Hepa1-6 cells (Figure 4C/D). These data supported Bmal1 as a positive regulator of Fmo5.

E4bp4 and Rev-erba regulate Fmo5 expression in primary mouse hepatocytes

The regulatory effects of E4bp4 and Rev-erba on Fmo5 expression were assessed using primary mouse hepatocytes. Overexpression of E4bp4 caused significant decreases in Fmo5 mRNA and protein, whereas E4bp4 knockdown resulted in an increase in Fmo5 expression, revealing E4bp4 as a negative regulator of Fmo5 (Figure 5A/B). We observed positive regulatory effects of Rev-erba on Fmo5 (i.e., a positive correlation between Fmo5 and Rev-erba expressions) (Figure 5C/D). This disfavored direct regulation of Fmo5 by Rev-erba because Rev-erba is a well-known transcriptional repressor (Yin et al., 2005). Instead, a negative mediator should be involved in positive regulation of Fmo5 by Rev-erba. Since E4bp4 is a known target gene of Rev-erba (Duez et al., 2008), it was reasoned that positive regulation of Fmo5 by Rev-erba was attained through trans-repression of E4bp4, a negative regulator of Fmo5 (Figure 5C/D). This was supported by the fact that the regulatory effects of Rev-erba on Fmo5 were attenuated in E4bp4-deficient cells (Figure 5E).

Transcriptional regulation of *Fmo5* by circadian clock genes

Computational algorithm (jaspar.genereg.net) predicted one potential E-box (-1822/-1816 bp) and three potential D-boxes (named D-box¹, D-box², and D-box³) but no RevRE element in *Fmo5* promoter (Figure 6A). Bmal1 dose-dependently induced *Fmo5*-Luc reporter (-2000/+100 bp) activity (Figure 6B). Truncation and mutation experiments demonstrated that -1816 bp E-box was essential for Bmal1 effect (Figure 6C). A significant recruitment of Bmal1 protein to -1816 bp E-box was confirmed using ChIP assays (Figure 6D). These data indicated that Bmal1 directly trans-activated *Fmo5* through binding to an E-box in the gene promoter.

E4bp4 inhibited *Fmo5*-Luc reporter activity in a dose-dependent fashion, indicating a transcriptional repressive effect of E4bp4 on *Fmo5* (Figure 7A). Promoter analysis indicated that both D-box¹ and D-box³ were essential for E4bp4 effect, whereas D-box² made no contributions (Figure 7B). ChIP assays confirmed binding of both D-box¹ and D-box³ to E4bp4 protein (Figure 7C). These data established E4bp4 as a direct repressor of *Fmo5*. Dbp is a transcription factor reported to compete for the D-box to antagonize the trans-repression effects of E4bp4 (Mitsui et al., 2001; Yu et al., 2019). In an identical manner, we found that Dbp trans-activated *Fmo5* through direct binding to D-box¹ in the gene promoter (Figure 7D/E/F).

Discussion

In this study, we reported diurnal expression and activity of *Fmo5* in mouse liver (Figures 1-2). Moreover, we uncovered the molecular mechanism by which the rhythmic *Fmo5* expression was generated (Figure 8). To be specific, *Fmo5* promoter presents E-box and D-box binding elements for transcriptional actions from circadian clock proteins such as *Bmal1*, *E4bp4* and *Dbp* (Figure 8). In addition to direct trans-activation, the E-box binding protein *Bmal1* may indirectly regulate the transcription of *Fmo5* through *Dbp* and *Rev-erba*/*E4bp4* axis (Figure 8). This is because *Dbp* and *Rev-erba* are known target genes of *Bmal1* and *E4bp4* is a known target of *Rev-erba* (Yamaguchi et al., 2000; Mukherji et al., 2013; Yu et al., 2019). The indirect regulation mechanism was supported by the fact that hepatic *Dbp* and *Rev-erba* were down-regulated, whereas *E4bp4* was up-regulated in *Bmal1*^{-/-} mice (Supplementary Figure S3).

Identifying circadian genes among drug-processing genes and elucidating the circadian regulation mechanisms are essential to advance chronopharmacology. Although a number of drug-processing genes are subjected to diurnal variations based on an mRNA determination (Zhang et al., 2009), little is known regarding the circadian mechanisms regulating these genes. This is the first report revealing the molecular mechanisms controlling the diurnal expression of *Fmo5*, a non-CYP phase I enzyme. Since *Fmo5* regulates metabolic aging via pleiotropic effects including effects on fatty

acid oxidation and biosynthesis of triglyceride, lipid and cholesterol (Gonzalez Malagona et al., 2015), there is a possibility that this enzyme contributes to circadian hemostasis of endogenous substances.

We observed consistent diurnal patterns (peaks at the late light phase) between the regulator (Bmal1, Dbp and Rev-erba) protein and Fmo5 mRNA, supporting positive transactivation of Fmo5 by these three factors (Figure 8; Yu et al., 2019). Moreover, E4bp4 protein oscillated in anti-phase to Fmo5 mRNA consistent with a negative regulation mechanism (Figure 8; Yu et al., 2019). Our data lend support to the notion that Dbp and E4bp4 play an antagonistic role in gene regulation (Mitsui et al., 2001; Figure 8). Dbp action (induction of Fmo5 expression) dominates in the daytime period, whereas E4bp4 action (inhibition of Fmo5 expression) dominates in the night, thereby contributing a diurnal oscillation in Fmo5 expression (Figure 8).

Chronopharmacokinetic experiments with PTX revealed a more extensive formation of PTX-M (an Fmo5-dependent metabolite) at dosing time of ZT14 than at ZT2 consistent with the circadian time differences in Fmo5 expression (Figures 1-2). However, the pharmacokinetic behavior of PTX was dosing time-independent although slight differences in plasma/liver concentrations were observed (Figure 2). This was probably because PTX-M formation by Fmo5 was a non-major metabolic pathway for PTX as CYP enzymes make a significant contribution (Peterson et al., 2004; Uney et al., 2019). Alterations in a non-major metabolic pathway may not cause sufficient changes in total

parent drug metabolism and pharmacokinetics.

The current study and our previous studies support the notion that drug metabolism is under the control of the circadian clock (Zhang et al., 2018; Zhao et al., 2018; Guo et al., 2019). Clock-controlled metabolism is associated with time-dependent pharmacokinetics, drug toxicity and effects (Johnson et al., 2014). We show herein that diurnal *Fmo5* expression was regulated through the cis-acting elements E-box and D-box. A diurnal rhythm in FMO expression was also noted in rabbit lung (Smart et al., 2013). By using computational algorithm (jaspar.genereg.net), we identified potential E-box and D-box elements in promoter regions of other four *Fmo* genes (i.e. *Fmo1*, *Fmo2*, *Fmo3* and *Fmo4*) (Supplementary Figure S4). Therefore, it is highly possible that *Fmo1-4* are also circadian genes and regulated by E-box and D-box binding proteins.

Serum shock experiment was performed to confirm the rhythmic expression of *Fmo5* at a cellular level because a serum shock (50% serum) can induce circadian gene expression in the cells (Balsalobre et al., 1998). Mechanistically, a high level of serum activates serum response factor (SRF) to stimulate the expressions of target genes including circadian clock genes *Bmal1* and *Per*, inducing circadian gene expression (Gerber et al., 2013). *Fmo5* mRNA appears to oscillate with a period of around 24 h in serum-shocked cells (Figure 1E). However, the amplitude was attenuated during the second period (Figure 1E). This is normal because serum shock effect is time-dependent, becoming weaker at a later stage (Murakami et al., 2008; Matsunaga et al., 2008; Yu et

al; 2019).

CLOCK is another E-box binding protein (Preitner et al., 2002). We attempted to validate the role of E-box element in rhythmic regulation of *Fmo5* using *Clock*^{-/-} mice. Clock ablation led to down-regulation of *Fmo5* expression and loss of diurnal rhythm in mouse liver (Supplementary Figure S5). The data strongly supported a critical role for E-box transcription in generation of *Fmo5* rhythmicity. It is noteworthy that an E-box (-581/-575 bp) and a D-box (-600/-589 bp) can be found in promoter region of human *FMO5* gene. There is a possibility that human *FMO5* is a circadian gene and controlled by E-box and D-box binding proteins. However, whether this is true or not awaits further investigations.

In summary, we showed diurnal rhythms of hepatic *Fmo5* at the levels of mRNA, protein and enzymatic activity. *Fmo5* rhythms were generated through transcriptional actions of circadian clock genes (including *Bmal1*, *E4bp4* and *Dbp*) on E-box and D-box cis-elements. Our study has implications for understanding of clock-controlled drug metabolism and for facilitating the practice of chronotherapeutics.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grants 81722049 and 81573488), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (Grant 2017BT01Y036), the Natural Science Foundation of Guangdong Province (Grant 2017A03031387), the Guangzhou Science and Technology Project (Grant 201904010472), and the China Postdoctoral Science Foundation (Grant 2019M650234).

Authorship Contributions

Participated in research design: Chen, Guan, Zhang and Wu.

Conducted experiments: Chen, Guan and Xu

Performed data analysis: Chen, Yu, Zhang and Wu.

Wrote the manuscript: Chen and Wu.

References

Balsalobre A, Damiola F, and Schibler U (1998) A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell* 93(6):929-937.

Cashman JR, and Zhang J (2006) Human flavin-containing monooxygenases. *Annu Rev Pharmacol Toxicol* 46:65-100.

Chen M, Guo L, Dong D, Yu F, Zhang T, and Wu B (2019) The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice. *Biochem Pharmacol* 161:163-172.

Duez H, van der Veen JN, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Baugé E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennström B, Kuipers F, and Staels B (2008) Regulation of bile acid synthesis by the nuclear receptor Rev-erb α . *Gastroenterology* 135(2): 689-698.

Fiorentini F, Marco ER, OrcidKurt WF, Mélanie F, and Mattev HA (2017) Baeyer–Villiger Monooxygenase FMO5 as entry point in drug metabolism. *ACS Chem Biol* 12(9):2379-2387.

Gachon F, and Firsov D (2011) The role of circadian timing system on drug metabolism and detoxification. *Expert Opin Drug Metab Toxicol* 7(2):147-158.

Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, Takahashi JS, and Weitz CJ (1998) Role of the CLOCK protein in the mammalian circadian mechanism. *Science* 280(5369):1564-9.

Gerber A, Esnault C, Aubert G, Treisman R, Pralong F, and Schibler U (2013) Blood-borne circadian signal stimulates daily oscillations in actin dynamics and SRF activity. *Cell* 152:492–503.

Gonzalez Malagon SG, Melidoni AN, Hernandez D, Omar BA, Houseman L, Veeravalli S, Scott F, Varshavi D, Everett J, Tsuchiya Y, Timms JF, Phillips IR, and Shephard EA (2015) The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (Fmo5) as a regulator of metabolic ageing. *Biochem Pharmacol* 96(3):267-77.

Guo L, Yu F, Zhang T, and Wu B (2018) The Clock Protein *Bmal1* Regulates Circadian Expression and Activity of Sulfotransferase 1a1 in Mice. *Drug Metab. Dispos* 46(10):1403–1410.

Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. *Pharmacogenetics* 14(2):117–130.

Janmohamed A, Hernandez D, Phillips IR, and Shephard EA (2004) Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). *Biochem Pharmacol* 68(1):73-83.

Johnson BP, Walisser JA, Liu Y, Shen AL, McDearmon EL, and Moran SM (2014) Hepatocyte

circadian clock controls acetaminophen bioactivation through NADPH-cytochrome P450 oxidoreductase. *Proc Natl Acad Sci* 111 (52): 18757-18762.

Johnson BP, Walisser JA, Liu Y, Shen AL, McDearmon EL, Moran SM, McIntosh BE, Vollrath AL, Schook AC, Takahashi JS, and Bradfield CA (1999) mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. *Cell* 98(2):193-205.

Krueger SK, and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. *Pharmacol Ther* 106:357–387.

Lai WG, Farah N, Moniz GA, and Wong YN (2011) A Baeyer-Villiger Oxidation Specifically Catalyzed by Human Flavin-Containing Monooxygenase 5. *Drug Metab Dispos* 39(1): 61-70.

Malátková P, and Wsól V (2014) Carbonyl reduction pathways in drug metabolism. *Drug Metab Rev* 46(1):96–123.

Matsunaga N, Ikeda M, Takiguchi T, Koyanagi S, and Ohdo S (2008) The molecular mechanism regulating 24 hour rhythm of CYP2E1 expression in the mouse liver. *Hepatology* 48(1): 812-8582.

Matsunaga N, Inoue M, Kusunose N, Kakimoto K, Hamamura K, Hanada Y, Toi A, Yoshiyama Y, Sato F, Fujimoto K, Koyanagi S, and Ohdo S (2012) Time-dependent interaction between differentiated embryo chondrocyte-2 and CCAAT/enhancer-binding protein a underlies the circadian expression of CYP2D6 in serum-shocked HepG2 cells. *Mol Pharmacol* 81(5):739-747.

Minami Y, Ode KL, and Ueda HR (2013) Mammalian circadian clock: the roles of transcriptional repression and delay. *Handb Exp Pharmacol* 217:359-77.

Mitsui S, Yamaguchi S, Matsuo T, Ishida Y, and Okamura H (2001) Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. *Genes Dev* 15(8):995–1006.

Mukherji A, Kobiita A, Ye T, and Chambon P (2013) Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs. *Cell* 153(4): 812-827.

Murakami Y, Higashil Y, Matsunaga N, Koyanagi S, and Ohdo S (2008) Circadian clock-controlled intestinal expression of the multidrug-resistance gene *mdr1a* in mice. *Gastroenterology* 135(5):1636 –1644.

Nicklasson M, Bjorkman S, Roth B, Jonsson M, and Hoglund P (2002) Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. *Chirality* 14(8): 643–652.

Ohdo S, Koyanagi S, Suyama H, Higuchi S, and Aramaki H (2001) Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. *Nat Med* 7(3):356-360.

Ohmi N, Yoshida H, Endo H, Hasegawa M, Akimoto M, and Higuchi S (2003) S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. *Xenobiotica*. 33(12):1221-1231.

- Paschos GK, Baggs JE, Hogenesch JB, and FitzGerald GA (2010) The role of clock genes in pharmacology. *Annu Rev Pharmacol Toxicol* 50:187-214.
- Peterson TC, Peterson MR, Wornell PA, Blanchard MG, and Gonzalez FJ (2004) Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. *Biochem Pharmacol* 68(2): 395–402.
- Ralph MR, Foster RG, Davis FC, and Menaker M (1990) Transplanted suprachiasmatic nucleus determines circadian period. *Science* 247(4945):975-8.
- Raoul JM, Peterson MR, and Peterson TC (2007) A novel drug interaction between the quinolone antibiotic ciprofloxacin and a chiral metabolite of pentoxifylline. *Biochem Pharm* 74(4):639–646.
- Rendic S, and Guengerich FP (2015) Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. *Chem Res Toxicol* 28(1):38-42.
- Reppert SM, and Weaver DR (2002) Coordination of circadian timing in mammals. *Nature* 418:935–941.
- Samlaska CP, and Winfield EA (1994) Pentoxifylline. *J Am Acad Dermatol* 30(4):603–621.
- Uney K, Tras B, Corum O, Yildiz R, and Maden M (2019) Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. *Trop Anim Health Prod* 51(2):435–441.
- Wang S, Lin Y, Yuan X, Li F, Guo L, and Wu B (2018) *REV-ERB α* integrates colon clock with experimental colitis through regulation of NF- κ B/NLRP3 axis. *Nat Commun* 9:4246.
- Yamaguchi S, Mitsui S, Yan L, Yagita K, Miyake S, and Okamura H (2000) Role of DBP in the Circadian Oscillatory Mechanism. *Mol Cell Biol* 20(13): 4773-4781.
- Yin L, and Lazar MA (2005) The orphan nuclear receptor Rev-erb α recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian *Bmal1* gene. *Mol Endocrinol* 19(6):1452-9.
- Yu F, Zhang T, Zhou C, Xu H, Guo L, Chen M, and Wu B (2019) The circadian clock gene *Bmal1* controls intestinal exporter MRP2 and drug disposition. *Theranostics* 9(10): 2754-2767.
- Zhang T, Guo L, Yu F, Chen M, and Wu B (2019) The nuclear receptor Rev-erb α participates in circadian regulation of *Ugt2b* enzymes in mice. *Pharmacology* 161:89–97.
- Zhang T, Yu F, Guo L, Chen M, Yuan X, and Wu B (2018) Small heterodimer partner regulates circadian cytochromes p450 and drug-induced hepatotoxicity. *Theranostics* 8(19): 5246-5258.
- Zhang T, Zhao M, Lu D, Wang S, Yu F, Guo L, and Wu B (2018) REV-ERB α regulates CYP7A1 through repression of liver receptor homolog-1. *Drug Metab Dispos* 46(3): 248–258.
- Zhang W, Sargis RM, Volden PA, Carmean CM, Sun XJ, and Brady MJ (2012) PCB 126 and other dioxin-like PCBs specifically suppress hepatic PEPCK expression via the aryl hydrocarbon receptor. *PLoS One* 7(5):e37103.

Zhang YJ, Yeager RL, and Klaassen CD (2009) Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. *Drug Metab Dispos* 37 (1) 106-115.

Zhao M, Zhang T, Yu F, and Guo L, and Wu B (2018) *E4bp4* regulates carboxylesterase 2 enzymes through repression of the nuclear receptor Rev-erb α in mice. *Biochem Pharmacol* 152:293–301.

Footnotes

MC and BG contribute equally to this work.

Legends for Figures

Figure 1 Diurnal rhythm of *Fmo5* expression in mouse liver and Hepa1-6 cells. (A)

Diurnal rhythm of *Fmo5* mRNA in mouse liver. Data are presented as the fold change in *Fmo5* expression normalized to *Ppib* and relative to ZT2. (B) Rhythmic *Fmo5* protein expression in mouse liver. Data are presented as the fold change in *Fmo5* protein expression normalized to *Gapdh* and relative to ZT2. (C) Chemical structures of PTX and the *Fmo5*-catalyzed metabolite PTX-M. (D) Diurnal rhythm of *Fmo5* activity in mouse liver microsomes. (E) Temporal mRNA expression of *Fmo5* in serum-shocked Hepa1-6 cells. Data are presented as the fold change in *Fmo5* expression normalized to *Ppib* and relative to time 0. Data are mean \pm SD ($n = 5$). $*p < 0.05$ (one-way ANOVA). The dark phase (lights off) is indicated in grey. Rel, Relative.

Figure 2 Dosing time-dependent PTX-M formation from PTX in mice. (A) Plasma

PTX concentration-time profile after dosing of PTX (50mg/kg, i.p.) at ZT2 or ZT14. (B) Liver PTX concentration-time profile after dosing of PTX (50mg/kg, i.p.) at ZT2 or ZT14. (C) Plasma concentration-time profile of PTX-M after PTX administration (50mg/kg, i.p.) at ZT2 and ZT14. (D) Liver concentration-time profile of PTX-M after PTX administration (50mg/kg, i.p.) at ZT2 and ZT14. Data are presented as mean \pm SD ($n = 5$). $*p < 0.05$ versus ZT2 at individual time points (two-way ANOVA and Bonferroni post hoc test).

Figure 3 Disrupted rhythms of *Fmo5* in *Bmal1*^{-/-}, *Rev-erba*^{-/-}, and *E4bp4*^{-/-} mice. (A)

qPCR analyses of *Fmo5* in mouse livers of *Bmal1*^{-/-}, *Rev-erba*^{-/-}, and *E4bp4*^{-/-} mice and their control littermates. Data are presented as the fold change in *Fmo5* expression normalized to *Ppib* and relative to ZT2 of control littermates. (B) Western blotting analyses of *Fmo5* protein in mouse liver of *Bmal1*^{-/-},

Rev-erba^{-/-}, *E4bp4*^{-/-} mice and their control littermates. Data are presented as the fold change in *Fmo5* protein expression normalized to *Gapdh* and relative to ZT2 of control littermates. Data are mean \pm SD ($n = 5$). * $p < 0.05$ between different genotypes at individual time points (two-way ANOVA and Bonferroni post hoc test). The dark phase (lights off) is indicated in grey. Rel, Relative.

Figure 4 Bmal1 regulates Fmo5 expression in primary mouse hepatocytes and Hepa1-6 cells. (A) *Fmo5* mRNA expression in primary mouse hepatocytes transfected with *Bmal1* expression plasmid or si*Bmal1*. **(B)** *Bmal1* induces *Fmo5* protein expression in primary mouse hepatocytes. **(C)** *Fmo5* mRNA expression in Hepa1-6 cells transfected with *Bmal1* expression plasmid or si*Bmal1*. **(D)** *Bmal1* induces *Fmo5* protein expression in Hepa1-6 cells. Data are mean \pm SD ($n = 5$). * $p < 0.05$ (t test). Rel, Relative.

Figure 5 E4bp4 and Rev-erba regulate Fmo5 expression in primary mouse hepatocytes. (A) Effects of *E4bp4* overexpression or knockdown on *Fmo5* mRNA expression. **(B)** *E4bp4* represses *Fmo5* protein expression. **(C)** Effects of *Rev-erba* overexpression or knockdown on *Fmo5* mRNA expression. **(D)** *Rev-erba* positively regulates *Fmo5* protein expression. **(E)** Regulatory effects of *Rev-erba* on *Fmo5* are attenuated in *E4bp4*-deficient cells. Data are mean \pm SD ($n = 5$). * $p < 0.05$ (t test). Rel, Relative.

Figure 6 Bmal1 directly regulates Fmo5 expression through binding to an E-box element. (A) Schematic representation of E-box and D-box elements in *Fmo5* promoter region. **(B)** HEK293T cell based luciferase reporter assays. The cells were transfected with *Fmo5*-Luc reporter (200 ng) and *Bmal1* expression plasmid (100, 200 and 300 ng) or control. **(C)** HEK293T cell based luciferase reporter assays. The cells were transfected with truncated or mutated versions of *Fmo5* promoter (200 ng) and *Bmal1* expression plasmid (300 ng).

(D) ChIP assays showing recruitment of Bmal1 protein to *Fmo5* promoter (-1822 to -1816 bp region, an E-box element). An E-box of Dbp and a non-specific (distal) sequence (Table 1) were used as positive and negative controls respectively. Data are mean \pm SD ($n = 5$). $*p < 0.05$ (t test).

Figure 7 E4bp4 and Dbp directly regulate Fmo5 expression through binding to D-box elements. (A) E4bp4 dose-dependently suppresses *Fmo5* promoter activity. **(B)** Effects of E4bp4 on *Fmo5*-Luc (truncated and mutated versions) reporter activity. **(C)** ChIP assays showing recruitment of E4bp4 protein to *Fmo5* promoter. **(D)** Dbp dose-dependently increases *Fmo5* promoter activity. **(E)** Effects of Dbp on *Fmo5*-Luc (truncated and mutated versions) reporter activity. **(F)** ChIP assays showing recruitment of Dbp protein to *Fmo5* promoter. A D-box of Per2 and a non-specific (distal) sequence (Table 1) were used as positive and negative controls respectively. Data are mean \pm SD ($n = 5$). $*p < 0.05$ (t test).

Figure 8 Schematic diagram illustrating the molecular mechanism for generation of rhythmic Fmo5 expression. *Fmo5* promoter presents E-box and D-box binding elements for transcriptional actions from circadian clock proteins such as Bmal1, E4bp4 and Dbp. In addition to direct trans-activation, the E-box binding protein Bmal1 indirectly regulates the transcription of *Fmo5* through Dbp and Rev-erba/E4bp4 axis. Dashed arrows denote established regulatory pathways in the literature.

Tables

Table 1 Oligonucleotides used in this study.

	Forward (5'-3' sequence)	Reverse (3'-5' sequence)
qPCR		
Bmal1	CTCCAGGAGGCAAGAAGATTC	ATAGTCCAGTGGAAAGGAATG
Rev-erba	TTTTTCGCCGGAGCATCCAA	ATCTCGGCAAGCATCCGTTG
E4bp4	CTTTCAGGACTACCAGACATCCAA	GATGCAACTTCCGGCTACCA
Dbp	ACATCTAGGGACACACCCAGTC	AAGTCTCATGGCCTGGAATG
Fmo5	GAGGGCTTGGAACTGTCTG	CACGGACTGGTAAATACTGGC
Ppib	TCCACACCCTTTTCCGGTCC	CAAAAGGAAGACGACGGAGC
ChIP		
Dbp-E-box	TGGGACGCCTGGGTACAC	GGGAATGTGCAGCACTGGTT
Per2-D-box	TTGACGCGGCGAAGCGGTGAGTG	GGGACGCAGTGTGAACCTGG
Fmo5-E-box	TTCCAATGGTAAGTCCG	GTCTTGGCTGAAGGATAG
Fmo5-D-box ¹	TGGCTTCCACTGCTATCC	TGAACCCAGGTCTTCTGC
Fmo5-D-box ³	GCTTGCTTCCTGGGTTGG	GGTTCAGTATCTCCCTTCC
Fmo5-distal	GGTAACCCAACGGCAACT	CTCACAGACATTCCCAA
siRNA		
siBmal1	GCUCUUUCUUCUGUAGAAUTT	AAAGAUUUCUUCUCCUCGGTT
siRev-erba	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT
siE4bp4	GCACAAGCUUCGAUUAAT	UUUAAUCCGAAGCUUGCTT
siNC	CGAUUAGUCUAUACGUUCUCCUG	CUCAGGAGAACGUUAGACUAAUC

Table 2 Pharmacokinetic parameters derived from PTX concentration-time profiles.

PTX (50 mg/kg, i.p.) was administered to WT mice at ZT2 or ZT14.

Parameter	Unit	ZT2	ZT14
Liver			
AUC	ng/ml*h	232 ± 35.9	219 ± 24.5
MRT	h	0.30 ± 0.04	0.73 ± 0.13*
V _{ss}	L/kg	0.14 ± 0.05	0.41 ± 0.16
CL	L/h/kg	0.21 ± 0.03	0.22 ± 0.03
Plasma			
AUC	ng/ml*h	232 ± 40.8	222 ± 26.9
MRT	h	0.19 ± 0.01	0.19 ± 0.01
V _{ss}	L/kg	0.04 ± 0.01	0.04 ± 0.01
CL	L/h/kg	0.23 ± 0.04	0.23 ± 0.03

**p*<0.05 versus ZT2.

Table 3 Pharmacokinetic parameters derived from PTX-M concentration-time profiles. PTX (50 mg/kg, i.p.) was administered to WT mice at ZT2 or ZT14.

Parameter	Unit	ZT2	ZT14
Liver			
AUC	ng/ml*h	25.4 ± 0.71	54.8 ± 2.5*
MRT	h	1.62 ± 0.02	0.50 ± 0.03*
V _{ss}	L/kg	3.75 ± 1.46	0.66 ± 0.08*
CL	L/h/kg	1.48 ± 0.13	1.12 ± 0.23*
Plasma			
AUC	ng/ml*h	115 ± 13.0	183 ± 12.1*
MRT	h	0.43 ± 0.01	0.41 ± 0.01*
V _{ss}	L/kg	0.26 ± 0.01	0.25 ± 0.05
CL	L/h/kg	0.32 ± 0.01	0.27 ± 0.01*

* $p < 0.05$ versus ZT2.

Figure 1




Figure 2







Figure 3




Figure 4




Figure 5




Figure 6







Figure 7




Figure 8

